The latest news: Toca5: A Phase 2/3 Randomized, Open Label Study of Toca 511™, a Retroviral Replicating Vector, Combined With Toca FC™ versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma The Tocagen trial has just opened! Our website and clinicaltrials.gov do not have the details yet, but if you are interested in this trial, call them and ask where it is being done. This is for people with recurrent GBM or Anaplastic Astrocytoma, who are going to have surgery. There is a video on how this works at http://www.tocagen.com/toca5/ This is one of my favorite new trials. (Disclaimer: Tocagen is a sponsor of the Musella Foundation) No Impact With Mifepristone in Patients With Meningioma This is a small study, but the patients in the placebo group did better than those who took Mifepristone for meningiomas. Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed Glioblastoma Patients? A Multi-center, Randomized, Parallel, Open-label, Phase II Clinical Trial. This has an interesting result: Using Temozolomide right after surgery compared to waiting until radiation starts resulted in a big increase in median overall survival, but a decrease in progression free survival. It makes a lot of sense to me to start the Temozolomide right away (although we have to study the effect on wound healing), but more research is needed to see why the progression free survival goes down while the overall survival goes up. Targeted treatment produces rapid shrinkage of recurrent, BRAF-mutant brain tumor This is only in 1 patient so far but may lead to a major breakthrough in the treatment of this tumor type since they reported that nearly all patients with this tumor type have the mutation this drug targets. Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness. This is just theoretical, but it makes sense to me. Might be worth trying to add Dapsone if you are on Erlotinib. At the least it will help the rash, and at best might kill the tumor better! BrainTumor Co-Payment Assistance Program Status: OPEN to new applicants
